Should I buy or sell ESSA Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EPIX shares. View EPIX analyst ratings or view top-rated stocks .

What is ESSA Pharma's stock price target for 2024?

1 equities research analysts have issued 12 month price targets for ESSA Pharma's shares. Their EPIX share price targets range from $17.00 to $17.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 236.0% from the stock's current price. View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts .

How have EPIX shares performed in 2023?

ESSA Pharma's stock was trading at $2.52 at the start of the year. Since then, EPIX shares have increased by 100.8% and is now trading at $5.06. View the best growth stocks for 2023 here .

When is ESSA Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 12th 2023. View our EPIX earnings forecast .

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) announced its earnings results on Thursday, November, 18th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL) , Aurinia Pharmaceuticals (AUPH) , Lipocine (LPCN) , Trevena (TRVN) , Allena Pharmaceuticals (ALNA) , Agile Therapeutics (AGRX) , Biopharmx (BPMX) , Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX) .

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (1.54%), Rhenman & Partners Asset Management AB (0.53%), Group One Trading L.P. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech. View institutional ownership trends .

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ESSA Pharma Stock Price, News & Analysis (NASDAQ:EPIX)

$5.05

-0.25 (-4.72%)

(As of 04:00 PM ET)

Compare

Today's Range: $4.91
▼
$5.36
50-Day Range: $2.74
▼
$6.00
52-Week Range: $2.29
▼
$6.40

Volume: 58,942 shs
Average Volume: 128,427 shs
Market Capitalization: $222.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

ESSA Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 236.0% Upside
$17.00 Price Target
Short Interest: Bearish
6.91% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$454,274 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.69) to ($1.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

709th out of 953 stocks

Pharmaceutical Preparations Industry

309th out of 405 stocks

3.5

Analyst's Opinion

Consensus Rating
ESSA Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.00, ESSA Pharma has a forecasted upside of 236.0% from its current price of $5.06.
Amount of Analyst Coverage
ESSA Pharma has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.91% of the float of ESSA Pharma has been sold short.
Short Interest Ratio / Days to Cover
ESSA Pharma has a short interest ratio ("days to cover") of 7.8.
Change versus previous month
Short interest in ESSA Pharma has recently increased by 1.47%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
ESSA Pharma does not currently pay a dividend.
Dividend Growth
ESSA Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EPIX.

0.6

News and Social Media Coverage

Search Interest
Only 1 people have searched for EPIX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
5 people have added ESSA Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ESSA Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $454,274.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
12.00% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for ESSA Pharma are expected to decrease in the coming year, from ($0.69) to ($1.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ESSA Pharma is -8.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ESSA Pharma is -8.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ESSA Pharma has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ESSA Pharma Stock (NASDAQ:EPIX)

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

EPIX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EPIX Stock News Headlines

November 24, 2023 | msn.com

ESSA Pharma director Franklin Berger buys common shares worth ~$133.3K

November 21, 2023 | finance.yahoo.com

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference

December 6, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 8, 2023 | finance.yahoo.com

ESSA Pharma to Present at the Jefferies London Healthcare Conference

October 31, 2023 | finance.yahoo.com

We Think ESSA Pharma (NASDAQ:EPIX) Can Afford To Drive Business Growth

October 30, 2023 | finance.yahoo.com

EPIX: Dose Escalation Data for Combination of Masofaniten (EPI-7386) and Enzalutamide Presented at PCF Retreat…

October 21, 2023 | finance.yahoo.com

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress

August 14, 2023 | finance.yahoo.com

EPIX: Phase 2 Trial of EPI-7386 in Combination with Enzalutamide to Initiate in Calendar 3Q23…

December 6, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

August 14, 2023 | finance.yahoo.com

ESSA Pharma Inc. (NASDAQ:EPIX) is definitely on the radar of hedge funds investors who own 39% of the company

August 8, 2023 | finance.yahoo.com

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023

June 6, 2023 | finance.yahoo.com

ESSA Pharma Appoints Lauren Merendino to its Board of Directors

June 1, 2023 | finance.yahoo.com

ESSA Pharma to Present at 2023 Jefferies Healthcare Conference

May 24, 2023 | finance.yahoo.com

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

May 18, 2023 | finance.yahoo.com

EPIX: Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide…

May 11, 2023 | finance.yahoo.com

ESSA Pharma to Present at JMP Securities Life Sciences Conference

May 9, 2023 | msn.com

ESSA Pharma: Q2 Earnings Insights

May 9, 2023 | finance.yahoo.com

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023

April 18, 2023 | finance.yahoo.com

ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 15, 2023 | ca.finance.yahoo.com

ESSA Pharma Inc. (EPIX)

April 12, 2023 | finance.yahoo.com

ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer

March 8, 2023 | finance.yahoo.com

ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 7, 2023 | finance.yahoo.com

ESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures

February 23, 2023 | finance.yahoo.com

EPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide…

February 7, 2023 | finance.yahoo.com

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022

February 2, 2023 | finance.yahoo.com

ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference

January 25, 2023 | finance.yahoo.com

A Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

See More Headlines

Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/18/2021
Today: 12/06/2023
Next Earnings (Estimated): 12/12/2023
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EPIX
CUSIP: N/A
CIK: 1633932
Web: www.essapharma.com
Phone: 778-331-0962
Fax: 604-738-4080
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.00
High Stock Price Target: $17.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +236.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,100,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -17.25%
Return on Assets: -16.96%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 44.98
Quick Ratio: 44.98

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.79 per share
Price / Book: 1.34

Miscellaneous

Outstanding Shares: 44,100,000
Free Float: 38,809,000
Market Cap: $223.15 million
Optionable: Not Optionable
Beta: 1.97

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. David Ross Parkinson M.D. (Age 73)
President, CEO & Director
Comp: $798k
Mr. David S. Wood C.M.A. (Age 66)
CPA, CMA, CPA, M.B.A., MBA, Chief Financial Officer
Comp: $573.32k
Mr. Peter A. Virsik M.B.A. (Age 52)
M.S., Executive VP & COO
Comp: $625.36k
Dr. Alessandra Cesano M.D. (Age 62)
Ph.D., Chief Medical Officer & Executive VP
Comp: $598.03k
Chandtip Chandhasin
Executive
Erica Osbourne
Executive
Erin Rudsinski
Executive
Loleta Harris
Executive
Neil Thapar
Executive
Nkengyal Barber
Executive

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EPIX Stock Analysis - Frequently Asked Questions

Should I buy or sell ESSA Pharma stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EPIX shares.
View EPIX analyst ratings or view top-rated stocks.
What is ESSA Pharma's stock price target for 2024?: 1 equities research analysts have issued 12 month price targets for ESSA Pharma's shares. Their EPIX share price targets range from $17.00 to $17.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 236.0% from the stock's current price.
View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts.
How have EPIX shares performed in 2023?: ESSA Pharma's stock was trading at $2.52 at the start of the year. Since then, EPIX shares have increased by 100.8% and is now trading at $5.06.
View the best growth stocks for 2023 here.
When is ESSA Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 12th 2023.
View our EPIX earnings forecast.

How were ESSA Pharma's earnings last quarter?: ESSA Pharma Inc. (NASDAQ:EPIX) announced its earnings results on Thursday, November, 18th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03.
What other stocks do shareholders of ESSA Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX).
Who are ESSA Pharma's major shareholders?: ESSA Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (1.54%), Rhenman & Partners Asset Management AB (0.53%), Group One Trading L.P. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech.
View institutional ownership trends.
How do I buy shares of ESSA Pharma?: Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EPIX) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial